Published in J Virol on March 25, 2009
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med (2013) 1.45
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Innate immunity to adenovirus. Hum Gene Ther (2014) 1.15
Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet (2011) 1.10
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics (2014) 0.98
Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci Rep (2015) 0.93
Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood (2010) 0.92
Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol (2012) 0.90
Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol (2013) 0.90
CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther (2009) 0.88
The immunological properties of stroma-free polyhemolysate containing catalase and superoxide dismutase activities prepared by polymerized bovine stroma-free hemolysate. Artif Cells Blood Substit Immobil Biotechnol (2010) 0.87
Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses (2010) 0.87
Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. J Virol (2014) 0.87
Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J Innate Immun (2010) 0.85
IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells. PLoS Pathog (2014) 0.84
Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog (2015) 0.83
Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium. PLoS One (2011) 0.83
Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice. Hum Gene Ther (2011) 0.82
The role of endosomal escape and mitogen-activated protein kinases in adenoviral activation of the innate immune response. PLoS One (2011) 0.80
Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses (2010) 0.80
FX and host defense evasion tactics by adenovirus. Mol Ther (2013) 0.80
Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses. Sci Adv (2017) 0.80
Recent advances in gene therapy for lysosomal storage disorders. Appl Clin Genet (2015) 0.79
Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus. PLoS One (2014) 0.78
E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids (2016) 0.77
Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses. Pharmaceutics (2011) 0.76
The spread of adenoviral vectors to central nervous system through pathway of cochlea in mimetic aging and young rats. Gene Ther (2015) 0.76
RAG-1-deficient mice have no mature B and T lymphocytes. Cell (1992) 20.97
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods (1994) 13.53
The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature (2008) 9.01
How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8.63
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Complement evasion by human pathogens. Nat Rev Microbiol (2008) 4.24
Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol (2005) 3.04
The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol (1997) 2.84
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther (2001) 2.83
Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther (2001) 2.53
The role of the adenovirus protease on virus entry into cells. EMBO J (1996) 2.44
Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 2.36
Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol (2007) 2.33
Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 2.19
Membrane complement regulatory proteins. Clin Immunol (2005) 2.13
Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 1.93
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther (2003) 1.85
Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol (2007) 1.84
Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol (2008) 1.76
Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther (2007) 1.69
Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol (2003) 1.66
Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res (2007) 1.64
The alternative complement pathway revisited. J Cell Mol Med (2008) 1.62
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther (2004) 1.60
Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J Immunol (2000) 1.59
Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest (1975) 1.59
C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol (2008) 1.59
"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol (2001) 1.53
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther (2005) 1.52
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol (2008) 1.44
Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther (2005) 1.40
The role of complement in danger sensing and transmission. Immunol Res (2006) 1.36
Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther (1999) 1.32
Complement activation by recombinant adenoviruses. Gene Ther (2001) 1.31
Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther (2000) 1.29
Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol (2008) 1.29
Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther (2008) 1.28
Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther (2004) 1.26
Ficolin-2 recognizes DNA and participates in the clearance of dying host cells. Mol Immunol (2006) 1.23
A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther (2003) 1.22
Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther (2008) 1.21
Virus assembly and disassembly: the adenovirus cysteine protease as a trigger factor. Rev Med Virol (1998) 1.21
Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol (1990) 1.19
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther (2006) 1.18
Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther (2008) 1.16
Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther (2007) 1.15
Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol (2001) 1.14
Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol (2008) 1.11
Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol Ther (2007) 1.10
Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther (2008) 1.10
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 1.08
Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol (1992) 1.07
Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ (2001) 1.07
Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol (2005) 1.00
Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus. Gene Ther (2004) 0.99
Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Ther (2004) 0.97
Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther (2004) 0.95
Nonimmune activation of the classical complement pathway. Behring Inst Mitt (1993) 0.94
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology (2008) 0.94
A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods (2007) 0.93
Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem (1999) 0.92
Complement: an efficient sword of innate immunity. Contrib Microbiol (2008) 0.88
The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett (2008) 0.87
Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses. Mol Ther (2005) 0.85
Complement component C1q and anti-hexon antibody mediate adenovirus infection of a CAR-negative cell line. Viral Immunol (2008) 0.77
Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt (2007) 3.04
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell (2007) 2.83
Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature (2012) 2.19
Calorie restriction extends the chronological lifespan of Saccharomyces cerevisiae independently of the Sirtuins. Aging Cell (2007) 2.11
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol (2008) 1.93
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
RPD3 is required for the inactivation of yeast ribosomal DNA genes in stationary phase. EMBO J (2002) 1.79
Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol Cell Biol (2004) 1.73
Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res (2008) 1.70
Protection of the coronary arteries during epicardial radiofrequency ablation with intracoronary chilled saline irrigation: assessment in an in vitro model. J Cardiovasc Electrophysiol (2006) 1.70
Telomeric and rDNA silencing in Saccharomyces cerevisiae are dependent on a nuclear NAD(+) salvage pathway. Genetics (2002) 1.60
Characterization of species C human adenovirus serotype 6 (Ad6). Virology (2011) 1.59
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 1.57
A microarray-based genetic screen for yeast chronological aging factors. PLoS Genet (2010) 1.53
Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther (2005) 1.52
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
DNA replication stress is a determinant of chronological lifespan in budding yeast. PLoS One (2007) 1.46
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med (2013) 1.45
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
RNA polymerase I propagates unidirectional spreading of rDNA silent chromatin. Cell (2002) 1.35
Diversity in the Sir2 family of protein deacetylases. J Leukoc Biol (2004) 1.33
Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther (2003) 1.33
Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors. Biol Psychiatry (2010) 1.28
Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther (2008) 1.28
Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One (2009) 1.26
Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther (2004) 1.26
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology (2009) 1.23
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
Distinguishing the roles of Topoisomerases I and II in relief of transcription-induced torsional stress in yeast rRNA genes. Mol Cell Biol (2010) 1.21
Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther (2008) 1.16
Undergraduate neuroscience faculty: results from a survey of faculty for undergraduate neuroscience members. J Undergrad Neurosci Educ (2010) 1.15
Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther (2009) 1.15
Bipolar ablation of the interventricular septum is more efficient at creating a transmural line than sequential unipolar ablation. Pacing Clin Electrophysiol (2010) 1.15
Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther (2004) 1.15
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol (2010) 1.13
Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology (2006) 1.11
Calorie restriction effects on silencing and recombination at the yeast rDNA. Aging Cell (2009) 1.10
Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol (2011) 1.09
Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX. J Virol (2006) 1.09
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 1.08
Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine (2007) 1.08
A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci U S A (2004) 1.08
Sir Antagonist 1 (San1) is a ubiquitin ligase. J Biol Chem (2004) 1.06
Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci (2012) 1.04
Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther (2008) 1.01
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses (2009) 1.01
In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther (2003) 1.01
Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol (2011) 1.00
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release (2005) 0.97
Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology (2011) 0.97
The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol (2002) 0.96
Systemic delivery of therapeutic viruses. Curr Opin Mol Ther (2009) 0.96
Evaluation of bone regeneration by DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in a critical-sized calvarial defect. J Biomed Mater Res A (2006) 0.95
Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther (2011) 0.95
Characterization of DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in vitro. J Biomed Mater Res A (2006) 0.95
Heparin-binding and patterns of virulence for two recombinant strains of Sindbis virus. Virology (2005) 0.95
Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther (2004) 0.95
Targeting adenoviruses with factor x-single-chain antibody fusion proteins. Hum Gene Ther (2010) 0.95
Thiamine biosynthesis in Saccharomyces cerevisiae is regulated by the NAD+-dependent histone deacetylase Hst1. Mol Cell Biol (2010) 0.93
A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods (2007) 0.93
Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum Gene Ther (2011) 0.93
Genome-wide analysis of functional sirtuin chromatin targets in yeast. Genome Biol (2013) 0.93
Genetic identification of factors that modulate ribosomal DNA transcription in Saccharomyces cerevisiae. Genetics (2009) 0.93
Yeast sirtuins and the regulation of aging. FEMS Yeast Res (2013) 0.92
Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules (2008) 0.92
Deoxyribonuclease II is a lysosomal barrier to transfection. Mol Ther (2003) 0.91
Transcription of multiple yeast ribosomal DNA genes requires targeting of UAF to the promoter by Uaf30. Mol Cell Biol (2008) 0.91
Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol (2009) 0.91
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech (2013) 0.91
A library-selected, Langerhans cell-targeting peptide enhances an immune response. DNA Cell Biol (2004) 0.90
Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol (2013) 0.90
Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther (2004) 0.90
Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol (2005) 0.89
Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy. Hum Gene Ther (2009) 0.88
Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation (2013) 0.88
Comparison of electroanatomic contact and noncontact mapping of ventricular scar in a postinfarct ovine model with intramural needle electrode recording and histological validation. Circ Arrhythm Electrophysiol (2008) 0.87
Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One (2011) 0.87
Progressive changes in hepatoma cells stably transfected with hepatitis B virus X gene. Intervirology (2008) 0.87
Sequence and structural evolution of the KsgA/Dim1 methyltransferase family. BMC Res Notes (2008) 0.86
Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res (2011) 0.86
Pnc1p-mediated nicotinamide clearance modifies the epigenetic properties of rDNA silencing in Saccharomyces cerevisiae. Genetics (2008) 0.86
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res (2003) 0.85
Structural and functional divergence within the Dim1/KsgA family of rRNA methyltransferases. J Mol Biol (2009) 0.85
Limiting the extent of the RDN1 heterochromatin domain by a silencing barrier and Sir2 protein levels in Saccharomyces cerevisiae. Mol Cell Biol (2009) 0.83
Isonicotinamide enhances Sir2 protein-mediated silencing and longevity in yeast by raising intracellular NAD+ concentration. J Biol Chem (2012) 0.83
Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB J (2012) 0.83
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One (2013) 0.83
Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. Biomaterials (2004) 0.83